The critical need for robust decision support in the era of precision cancer therapeutics

Maurie Markman

doi:10.37349/etat.2026.1002356

Exploration of Targeted Anti-tumor Therapy ›› 2026, Vol. 7 ›› Issue (1) :1002356 DOI: 10.37349/etat.2026.1002356

Editorial

research-article

The critical need for robust decision support in the era of precision cancer therapeutics

Maurie Markman ^*

Author information +

History +

PDF (473KB)

Abstract

Cite this article

Download citation ▾

Maurie Markman. The critical need for robust decision support in the era of precision cancer therapeutics. Exploration of Targeted Anti-tumor Therapy, 2026, 7 (1) : 1002356 DOI:10.37349/etat.2026.1002356

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Jabbour E, Kantarjian H. Chronic Myeloid Leukemia: A Review. JAMA. 2025; 333: 1618-29.

[2]	Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-92.

[3]	O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al.; IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348: 994-1004.

[4]	Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al.; IRIS Investigators. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017; 376: 917-27.

[5]	Björkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sjöberg J, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011; 29: 2514-20.

[6]	Ostrowski M, Jo Y, Chehade CH, Ozay ZI, Gebrael G, Sayegh N, et al. Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 Alterations. JAMA Netw Open. 2025; 8: e2534968.

[7]	Gouda MA, Nelson BE, Buschhorn L, Wahida A, Subbiah V. Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications. Clin Cancer Res. 2023; 29: 2753-60.

[8]	Yap TA, Ashok A, Stoll J, Mauer E, Nepomuceno VM, Blackwell KL, et al. Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines. JAMA Netw Open. 2022; 5: e2213070.

[9]	Burke W, Parens E, Chung WK, Berger SM, Appelbaum PS. The Challenge of Genetic Variants of Uncertain Clinical Significance: A Narrative Review. Ann Intern Med. 2022; 175: 994-1000.

[10]	Roncato R, Bignucolo A, Peruzzi E, Montico M, Mattia ED, Foltran L, et al. Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer: A Secondary Analysis of the PREPARE Randomized Clinical Trial. JAMA Netw Open. 2024; 7: e2449441.